(Q33659405)

English

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month [...]

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Rishi P Singh

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Sunil Srivastava

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Justis P Ehlers

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Rumneek Bedi

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Andrew P Schachat

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

0 references

publication date

1 June 2014

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

British Journal of Ophthalmology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

98 Suppl 1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

i22-27

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

14 July 2018

Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304798

21 January 2018

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

30 October 2018

What is new in the management of wet age-related macular degeneration?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033174

30 October 2018

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24836866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24836866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24836866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24836866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJOPHTHALMOL-2013-304798

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24836866%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33659405&oldid=1990588528"